The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...
According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...
Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...
A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.
Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard ...
Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...
retriever generates disease-specific transcriptional drug response signatures by merging transcriptional signatures over time, concentration, and cell-type. These signatures can then be matched to ...
Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback